Table 1.

Projections of cancer incidence

A country with publicly available cancer registry data (NS)	Population 2020 (million)	NS: extrapolated incidence (data from Fig. 1, Fig. 2a)			GC-Projected incidence
		2020	2030	2040	2020	2030	2040
Bulgaria	7.05	35,710	40,309	44,907	35,366	35,258	34,504
Croatia	4.27	26,358	30,233	34,104	25,454	26,851	27,845
Slovenia	2.08	13,027	15,367	17,708	13,934	16,004	17,417
Combined 3 SEE crude incidence on 100,000 (from Fig. 1b)		570	658	746
A country with no empirical data		NS Projected incidence using combined 3 SEE crude rates
Kosovo*	1.91	10,887				9,223	10,052
Montenegro	0.61	3,477	4,014	4,551	2,423	2,704	2,888
N. Macedonia	2.08	11,856	13,686	15,517	8,048	9223	10,052
Serbia	7.08	40,356	46,586	52,817	48,471	49,682	49,273
Albania	3.05	17,385	20,069	22,753	8,604	10,049	11,197
Bosnia and Herzegovina	3.85	21,945	25,333	28,721	14,771	16,638	17,231
Greece	10.76	61,332	70,801	80,270	68,725	76,568	84,507
Total SEE	42.74	242,333	278,966	315,595	233,854	252,200	264,966
Increase relative to the previous decade			+15%	+13%		+7.8%	+5.1%

Abbreviations: GC = Globocan; NS =national cancer statistics; SEE = South-East European.

Projections are calculated through (1) NS: available national statistics for Bulgaria, Croatia, and Slovenia, and the 3 SEE country combined crude incidence evaluated with linear regression from Figure 2b. The incidence in Albania, Bosnia and Hercegovina, Greece, Kosovo, Montenegro, North Macedonia, and Serbia was projected from the combined 3 SEE country crude incidence; (2) GC: projected incidences by Globocan. Herein, projections for Kosovo are not available.

Therefore, the data blanks for Kosovo are filled in by copying the Globocan data for North Macedonia.

^⁎Unavailable data for Kosovo. Data in the table are duplication of the Globocan data for North Macedonia.